Anti-Mbd4 / Methyl-CpG-binding domain protein 4

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. Mbd4 antibody detects Methyl-CpG-binding domain protein 4, a nuclear enzyme that couples DNA repair with epigenetic regulation by recognizing methylated DNA and mediating the excision of mismatched bases. Mbd4 functions as a bifunctional DNA glycosylase that specifically removes thymine or uracil mispaired with guanine within methylated CpG sites, thereby maintaining genomic stability and preventing mutation accumulation. The Mbd4 antibody is widely used in studies of DNA repair, epigenetics, and cancer biology to explore the connection between cytosine methylation and genome maintenance.Mbd4 is encoded by the MBD4 gene located on human chromosome 3q21.3. The protein contains two main functional domains: an N-terminal methyl-CpG-binding domain (MBD) that targets methylated DNA, and a C-terminal glycosylase domain that catalyzes base excision. Through these domains, Mbd4 directly interacts with DNA methyltransferases and participates in active DNA demethylation pathways. It also forms complexes with MLH1, a mismatch repair factor, integrating base excision repair with the mismatch repair system.The Mbd4 antibody typically detects a 63 kilodalton protein on western blot. Mbd4 is highly expressed in proliferative tissues and cells undergoing DNA replication. Functionally, loss of Mbd4 leads to increased mutation frequency at CpG sites, predisposing cells to carcinogenesis. Experimental models show that Mbd4-deficient mice accumulate G:T mismatches and are more susceptible to DNA damage induced by oxidative stress or alkylating agents.Beyond repair, Mbd4 plays an important role in apoptosis and gene silencing. It interacts with the tumor suppressor p53 and participates in transcriptional repression of methylated gene promoters. Dysregulation of Mbd4 expression or mutations in its glycosylase domain have been linked to colorectal cancer, glioma, and leukemia, where defective base excision repair contributes to genomic instability. NSJ Bioreagents provides a validated Mbd4 antibody optimized for western blot, immunohistochemistry, and chromatin studies, supporting research on DNA methylation maintenance, repair mechanisms, and epigenetic disease progression.